- Home
- CALC vs TPST Comparison
CALC vs TPST Comparison
Compare CALC & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- TPST
- Stock Information
- Founded
- CALC 2011
- TPST 2011
- Country
- CALC United States
- TPST United States
- Employees
- CALC N/A
- TPST N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- TPST Health Care
- Exchange
- CALC Nasdaq
- TPST Nasdaq
- Market Cap
- CALC 32.4M
- TPST 33.0M
- IPO Year
- CALC N/A
- TPST N/A
- Fundamental
- Price
- CALC $3.80
- TPST $7.76
- Analyst Decision
- CALC Strong Buy
- TPST Hold
- Analyst Count
- CALC 2
- TPST 3
- Target Price
- CALC $14.50
- TPST $30.00
- AVG Volume (30 Days)
- CALC 133.2K
- TPST 80.4K
- Earning Date
- CALC 08-11-2025
- TPST 08-07-2025
- Dividend Yield
- CALC N/A
- TPST N/A
- EPS Growth
- CALC N/A
- TPST N/A
- EPS
- CALC N/A
- TPST N/A
- Revenue
- CALC N/A
- TPST N/A
- Revenue This Year
- CALC N/A
- TPST N/A
- Revenue Next Year
- CALC N/A
- TPST N/A
- P/E Ratio
- CALC N/A
- TPST N/A
- Revenue Growth
- CALC N/A
- TPST N/A
- 52 Week Low
- CALC $1.42
- TPST $5.35
- 52 Week High
- CALC $5.97
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- CALC 73.90
- TPST 63.65
- Support Level
- CALC $3.37
- TPST $6.11
- Resistance Level
- CALC $4.26
- TPST $6.49
- Average True Range (ATR)
- CALC 0.41
- TPST 0.35
- MACD
- CALC 0.21
- TPST 0.03
- Stochastic Oscillator
- CALC 82.80
- TPST 100.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.